{"id":"W2301614008","doi":"10.1136/gutjnl-2015-311079","title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","year":2016,"lang":"en","type":"article","venue":"Gut","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":803,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"UCB Pharma; Takeda Pharmaceuticals International; Takeda Oncology; Genentech; Sanofi; Kyowa Hakko Kirin; Ironwood Pharmaceuticals, Incorporated; Celltrion; Wellcome Trust; Danone; Novo Nordisk; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Osiris Therapeutics; Celgene; Pfizer; Biogen; GlaxoSmithKline; Shire; IC Design Education Center; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Tillotts Pharma; Amgen; ActoGeniX; Dr. Falk Pharma; Abbott Laboratories","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Adverse effect; Inflammatory bowel disease; Gastroenterology; Placebo; Crohn's disease; Incidence (geometry); Hazard ratio; Surgery; Disease; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008194767,0.00006178429,0.00004962796,0.000005964462,0.00009619524,0.000007911937,0.00007241189,0.00003052577,0.00000749165],"category_scores_gemma":[0.0001796699,0.00003610719,0.00004600682,0.000008988847,0.0001528875,0.000002045265,0.00004598367,0.00001028189,0.000002678438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007057154,"about_ca_system_score_gemma":0.00008194453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001176632,"about_ca_topic_score_gemma":0.00002867104,"domain_scores_codex":[0.999572,0.0000343124,0.00009865195,0.0001291624,0.00004517379,0.0001207029],"domain_scores_gemma":[0.9995726,0.00003338319,0.00004159511,0.0001979273,0.00007507478,0.00007947413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.09163123,0.0003357638,0.05741441,0.000636689,0.00091764,0.0003086552,0.0005770457,0.00002203833,0.3453937,0.1367247,0.06648979,0.2995484],"study_design_scores_gemma":[0.001175831,0.00005225248,0.9322976,0.00001776131,0.00002031117,0.000001179235,0.00002338954,0.0000106043,0.005202149,0.001221575,0.05988358,0.00009376399],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967813,0.0002181744,0.001058179,0.0004470664,0.00008003758,0.0003552689,0.0004061158,0.000004925028,0.0006489452],"genre_scores_gemma":[0.9981505,0.0001418786,0.00006127369,0.00007372387,0.0001013068,0.00005269336,0.00001461923,0.000008889846,0.00139511],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8748832,"threshold_uncertainty_score":0.1472408,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006282906948736122,"score_gpt":0.2369828235608517,"score_spread":0.2306999166121156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}